Cannabis
Levin Health Explains the Process of Prescribing Medicinal Cannabis
<!– Name:DistributionId Value:8752921 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1266861 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:c97acef1-a932-4521-ab3c-5fc8cc5d19d2 –>
MELBOURNE, Australia, Feb. 22, 2023 (GLOBE NEWSWIRE) — In Australia, medicinal cannabis isn’t prescribed in the same way as other, more conventional treatment options. Since most medical cannabis products don’t appear on the Australian Register of Therapeutic Goods (ARTG)1, patients cannot simply visit a doctor and receive a prescription. Australian sports science company Levin Health is focused on researching, developing and commercialising a range of medicinal cannabis products initially for the treatment of pain, mental health disorders and sport-related ailments. Here they explain what the process looks like for patients.
Levin Health explains that while the first port of call is still discussing symptoms with a doctor, government approval will have to be sought by your prescriber before medicinal cannabis Melbourne and Australia-wide can be prescribed.
Medical marijuana’s Australia-wide is normally only prescribed if patients have already tried other treatment options, with little to no improvement in symptoms.
If the doctor believes medicinal cannabis could be suitable, they can apply for approval via the Therapeutic Goods Administration (TGA)2. The GP takes care of the application along with any approvals necessary in that particular state or territory.
If the GP is a registered ‘Authorised Prescriber’ by the TGA2, they usually don’t need approval for each individual patient. Otherwise, they can use the TGA’s Special Access Scheme3 to obtain approval. According to Levin Health, eligibility is assessed on a “case-by-case basis” and usually only if all other options have been exhausted. Other potential routes a doctor could take is to suggest patients for a clinical trial or refer them to a medical professional with more experience with medicinal cannabis.
If the doctor’s request is approved by the TGA, the patient will then receive a prescription. Levin Health explains that pharmacies don’t always stock medicinal cannabis products, so they may need to place an order. Approvals take an average of two business days4.
Patients are not able to apply directly to the TGA for medicinal cannabis. Only a doctor or nurse practitioners can obtain approvals and prescribe medical cannabis products such as CBD oil. Australia-wide, medicinal cannabis is a controlled product, so it’s important to never buy any products online that claim to contain medicinal cannabis. It can only be legally obtained with a prescription from a doctor.
Sources:
- Australian Register of Therapeutic Goods
- Therapeutic Goods Administration
- Australian Government Department of Health – Special Access Scheme
- The Victorian Government Department of Health
Contact Information:
Levin Health
Marketing Manager
[email protected]
1300 053 846
Related Images
Levin Health
This content was issued through the press release distribution service at Newswire.com.
Attachment
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
Cannabis
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis2 weeks ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Innocan1 week ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf1 week ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis1 week ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
SCHWAZZE2 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis2 days ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt1 day ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace